Latest Diabetic foot Stories
SKILLMAN, N.J., Aug. 7 /PRNewswire/ -- ConvaTec, a world-leading provider of innovative medical technologies for community and hospital care, today announced the launch of a new campaign and best practice statement supporting Versiva((R)) XC((R)) gelling foam dressing.
SAN DIEGO, Calif., July 28 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today provided an update on the completion of their MATRIX Phase 2b clinical study and announced plans to provide detailed safety and efficacy data for their Excellarate(TM) product candidate around the end of September.
FORT WORTH, Texas, July 7 /PRNewswire/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (WNDM.ob), announced today that it will exhibit at the New Cardiovascular Horizons and Management of the Diabetic Foot & Wound Healing (NCVH) conference in New Orleans July 9-11.
ASHBURN, Va., June 18 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced positive provisional findings from its three phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the treatment and prevention of infection in diabetic foot ulcers. Chronic ulcerations such as diabetic foot ulcers are often colonized or contaminated with bacterial pathogens that can prevent ulcers...
Diabetes rates have risen sharply in developed countries in the wake of the obesity epidemic, and an estimated 30 million Europeans live with the condition.
FARMINGDALE, N.Y., May 12 /PRNewswire-FirstCall/ -- Misonix, Inc.
SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that the Company will hold a conference call and webcast to discuss recent developments and future plans for its Excellarate(TM) clinical development program.
SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today announced significant new formulation enhancements for its Excellarate(TM) product candidate that are designed to simplify and broaden the use of Excellarate for diabetic ulcers, and also expand the potential applicability into a number of additional wound healing market opportunities, including pressure and venous stasis ulcers, as well as major surgical and...
SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today announced the completion of recruitment for the pioneering Phase 2b MATRIX clinical trial to evaluate the safety and efficacy of the Excellarate(TM) product candidate for the potential treatment of non-healing foot ulcers in patients with type I or type II diabetes.
ADDISON, Texas, May 5 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE AMEX: ULU) announced today that clinical evidence utilizing Altrazeal(TM) Nanoflex Transforming Powder Dressing has been published in the respected peer-reviewed publication, International Wound Journal.
- A handkerchief.
- Specifically— The legendary sweat-cloth; the handkerchief of St. Veronica, according to tradition miraculously impressed with the mask of Christ; also, the napkin about Christ's head (Johu xx. 7).
- In general, any miraculous portrait of Christ.